Hims & Hers: A Bold Buyback Amid Market Skepticism

The telehealth sector’s rising star, Hims & Hers, has made a dramatic move to demonstrate faith in its own valuation, authorizing a massive $250 million share repurchase initiative. This substantial capital return program arrives during a period of significant stock price weakness, creating a stark contrast between corporate confidence and market sentiment. Investors are left questioning whether this represents a strategic masterstroke or misguided corporate activism.

Strong Fundamentals Clash with Weak Share Performance

Operational metrics tell a compelling growth story that appears disconnected from the company’s market valuation. For the third quarter of 2025, Hims & Hers reported revenue reaching $599 million, representing a robust 49 percent year-over-year increase. The company continues to demonstrate improving profitability while expanding its subscriber base to nearly 2.5 million customers. Despite these solid operational achievements, the equity has failed to respond positively, creating a puzzling divergence between business performance and market valuation.

Timing Raises Strategic Questions

The announcement’s timing presents a particular point of interest. With shares trading more than 50 percent below their annual peak and having declined over 30 percent in the past month alone, management has chosen this depressed valuation level to launch its most ambitious buyback program to date. The new $250 million authorization dramatically exceeds the previous program by 150 percent and is structured to unfold over a three-year horizon.

Should investors sell immediately? Or is it worth buying Hims & Hers?

Chief Executive Officer Andrew Dudum has framed this decision as a response to the company’s perceived undervaluation. The buyback structure provides significant flexibility, permitting acquisitions through open market transactions, private placements, or trading plans. This adaptable approach allows the company to capitalize on favorable pricing opportunities while continuing to fund expansion initiatives, including recently disclosed discussions with Novo Nordisk regarding weight management pharmaceuticals.

Market Waits for Validation

The critical question facing investors is whether this substantial capital allocation represents a prudent investment in an undervalued asset or misdirected resources during a transformational growth phase. The company’s leadership has placed a significant bet on their assessment of intrinsic value, directly challenging the market’s current pricing. Coming financial results will determine whether management’s confidence proves warranted or whether skeptical investors correctly assessed the situation. This bold move ultimately positions the next several earnings reports as the definitive arbiter in this debate between corporate insight and market wisdom.